Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger, Salvatore Pisconti, Ilario Giovanni Rapposelli, Lorenza Rimassa, Chiara Rognone, Maria Grazia Rodriquenz, Lidia Rita Corsini, Daniele Santin, Aldo Scarpa, Mario Scartozzi, Hector Soto Parra, Giuseppe Tonini, Giampaolo Tortora, Paolo Tralongo, Nicola Silvestris
{"title":"意大利罕见胆道癌症倡议(IRaBiCa):由 Gruppo Oncologico dell'Italia Meridionale (GOIM) 与 Gruppo Italiano Colangiocarcinoma (GICO) 合作开展的一项多中心观察研究。","authors":"Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger, Salvatore Pisconti, Ilario Giovanni Rapposelli, Lorenza Rimassa, Chiara Rognone, Maria Grazia Rodriquenz, Lidia Rita Corsini, Daniele Santin, Aldo Scarpa, Mario Scartozzi, Hector Soto Parra, Giuseppe Tonini, Giampaolo Tortora, Paolo Tralongo, Nicola Silvestris","doi":"10.1177/03008916231222761","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap: a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants?Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected.</p><p><strong>Methods: </strong>An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers.Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes.</p><p><strong>Conclusions: </strong>We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"203-208"},"PeriodicalIF":2.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).\",\"authors\":\"Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger, Salvatore Pisconti, Ilario Giovanni Rapposelli, Lorenza Rimassa, Chiara Rognone, Maria Grazia Rodriquenz, Lidia Rita Corsini, Daniele Santin, Aldo Scarpa, Mario Scartozzi, Hector Soto Parra, Giuseppe Tonini, Giampaolo Tortora, Paolo Tralongo, Nicola Silvestris\",\"doi\":\"10.1177/03008916231222761\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap: a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants?Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected.</p><p><strong>Methods: </strong>An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers.Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes.</p><p><strong>Conclusions: </strong>We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.</p>\",\"PeriodicalId\":23349,\"journal\":{\"name\":\"Tumori\",\"volume\":\" \",\"pages\":\"203-208\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tumori\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/03008916231222761\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916231222761","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).
Introduction: About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap: a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants?Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected.
Methods: An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers.Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes.
Conclusions: We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.
期刊介绍:
Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.